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Abstract
There are proven pleiotropic anti-atherogenic actions of high-
density lipoprotein (HDL). However, in systemic inflammation, HDL
can have pro-inflammatory properties that may contribute to
accelerated atherosclerosis, likely mediated by a change in the
structure of HDL to pro-inflammatory HDL (PiHDL). Validation of
the technically challenging assay for PiHDL, and confirmation of an
association of PiHDL in multiple populations with known risk for
atherosclerosis will eventually provide a useful biomarker. Identifi-
cation of PiHDL in patients with rheumatic disease may help
identify patients at risk of accelerated atherosclerosis, and focus
our therapeutic interventions.
In the previous issue of Arthritis Research & Therapy, Hahn
and colleagues [1] provided a comprehensive review of
altered lipoprotein metabolism in chronic inflammatory states,
and proposed that this altered metabolism may be important
in the pathogenesis of accelerated atherosclerosis in rheu-
matic disease. Cardiovascular morbidity and mortality have
been associated with chronic rheumatic diseases, most
notably systemic lupus erythematosus (SLE) and rheumatoid
arthritis (RA). Although co-morbidities may frequently co-exist
in patients with RA and SLE as a complication of disease or
treatment, both SLE and RA have been identified as
independent risk factors for atherosclerotic cardiovascular
disease [2,3]. What factors or group of factors increase that
risk is under intense investigation. Lipids and lipoproteins
have been extensively studied, but have not been shown to
be a primary risk factor in SLE and RA. In cohorts of SLE
patients studied, cholesterol has not been an independent
predictor of atherosclerotic cardiovascular disease [4,5].
Additionally, although there has been a consistent pattern of
lower high-density lipoprotein (HDL) cholesterol levels seen
in RA patients compared with age- and sex-matched controls,
the picture is more mixed with regard to total cholesterol and
low-density lipoprotein (LDL) cholesterol levels [6,7]. There-
fore, if cholesterol metabolism and transport contribute to the
presence and progression of atherosclerosis in these
inflammatory states, it is reasonable to consider altered
lipoprotein states. In their review, Hahn and colleagues
present the accumulated data on pro-inflammatory HDL as a
novel biomarker for increased risk of atherosclerosis in
patients with SLE and RA.
HDL-cholesterol is considered among the best predictors of
cardiovascular disease in large populations. However, in the
original Framingham study approximately 44% of the events
in men and 43% in women occurred in persons with normal
HDL-cholesterol levels [8]. Research has proven the
pleiotropic anti-atherogenic actions of HDL, and Hahn and
colleagues review the three major protective mechanisms by
which HDL prevents atherosclerosis: through its role in
reverse cholesterol transport; through its antioxidative function,
especially with apoA-1 and apoE; and through direct
interactions with endothelial cells.
However, more than a decade ago, Van Lenten and
colleagues [9] reported that during an acute phase response
in animals or in humans following surgery, the properties of
HDL changed dramatically, and became pro-inflammatory.
These observations have spawned studies evaluating the pro-
inflammatory properties of HDL. The processes that account
for the modification of normal HDL to pro-inflammatory HDL
(PiHDL) are also reviewed in Hahn and colleagues’ article
and include: oxidation of lipoproteins in the HDL particle;
decreased synthesis of protective lipoproteins, especially
ApoA-1; and replacement of cholesterol transporting proteins
with pro-oxidants, including serum amyloid A and cerulo-
plasmin. When an acute phase response occurs, non-
specific immunity producing an oxidative environment takes
place. Thus, HDL appears to be part of the innate immune
system and can be either pro-inflammatory or anti-
inflammatory depending on the presence or absence of an
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acute phase response and the presence or absence of
systemic inflammation.
The assay used to measure PiHDL is a cell-free assay using
LDL as the fluorescence-inducing agent and is technically
challenging [10]. Replication has been difficult because of
the nuances of the assay. Nevertheless, this assay has been
used to study at least two populations, the first, an SLE and
RA population reported by Hahn’s group, and more recently,
a South Asian immigrant group.
MacMahon and colleagues [11] reported that SLE patients
had more PiHDL than matched controls (mean ± standard
deviation score of 1.02 ± 0.57 versus 0.68 ± 0.28 in controls
(p < 0.0001)) and that SLE patients with coronary artery
disease (CAD) had significantly higher PiHDL scores than
patients without CAD (p < 0.001). PiHDL was associated
with elevated levels of oxidized LDL.
Dodani and colleagues [12] studied a cohort of South Asian
immigrants, who have a higher risk for CAD compared to
Caucasians, and measured sub-clinical CAD using carotid
intima media thickness as a surrogate marker of athero-
sclerosis. On logistic regression analysis, positive carotid
intima media thickness was found to be associated with
PiHDL after adjusting for age, family history of cardiovascular
disease, and hypertension (p = 0.030).
These two studies suggest that HDL structure and function
may predict atherosclerotic cardiovascular disease better than
HDL-cholesterol levels. Although there is a need to replicate
and validate these findings in other populations, measurement
of PiHDL, along with other markers that correlate with
atherosclerotic cardiovascular disease such as homocysteine
[4,5], may help us better identify patients with rheumatic
disease who are at risk of cardiovascular events. Identification
of these patients will facilitate therapeutic interventions to
prevent the morbidity and mortality associated with
accelerated atherosclerosis in rheumatic diseases.
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